What changed today in Regulatory: 1 new study
Every new official record on the Pharmacy, Compounding & Regulatory Intelligence desk since this morning, each linked to its primary source.
Automated from official records1 source1 min read
GLP-1 compounding
Compounding of GLP-1 medicines by 503A pharmacies and 503B outsourcing facilities, and the regulatory questions raised when shortages are declared and resolved.
- Editorial attention
- Quiet
- Tracked this week
- 0
- Sources this week
- 0
- Last activity
- Oct 31, 2026
Signal strength reflects editorial attention across tracked sources — not medical certainty or strength of evidence.
- Pending editorial review
A system check is an automated check of the official sources, not a human review. An editorial review is recorded only when one of our editors has reviewed the page.
GLP-1 compounding at a glance
- About this topic
- Compounding of GLP-1 medicines by 503A pharmacies and 503B outsourcing facilities, and the regulatory questions raised when shortages are declared and resolved.
- Current status
- No editor-reviewed status summary yet. The official records below update automatically.
- Last updated
- Primary sources
- Latest official record: Pigmented purpura dermatosis associated with compounded semaglutide: A case report and literature review of medication-associated pigmented purpuric dermatosis (opens the source in a new tab) (JAAD case reports, Oct 31, 2026)
- Key facts from tracked records
- 3 NPHLA briefings on this topic
What’s the latest on GLP-1 compounding?
3 totalHow a drug’s place on FDA’s shortage list changes the compounding rules
When FDA lists a drug as in shortage, some federal limits on compounding copies of that drug stop applying; when FDA resolves the shortage, they return. Here is how that works for 503A pharmacies and 503B outsourcing facilities.
AI-assisted · Editor reviewed6 sources2 min read
503A or 503B? How the two federal compounding pathways differ — and why it mattered for GLP-1 medicines
Federal law gives compounders two routes, with different rules on prescriptions, quality standards, oversight and copies of approved drugs. Here is how they compare, using GLP-1 compounding as the worked example.
AI-assisted · Editor reviewed6 sources3 min read